• 한국식품과학회지
• /
• 제39권6호
• /
• pp.625-629
• /
• 2007

불가사리 골편의 콜라겐으로부터 활성 펩타이드를 분리하기 위하여 초음파를 처리하여 조직을 단편화 시키고 이후 collagnease를 처리하였다. 초음파를 처리할 경우 40kHz의 경우 38.89%의 수율을 나타내었다. 이후 펩타이드의 분자량을 측정하여 12, 20.6, 24, 43, 58a, 100, 116 kDa에서 특정 밴드를 보였다. 이후 Sephadex G-75 컬럼을 이용하여 fraction 별로 모아 사용하였다. 세포 독성을 측정하고 시료 처리 후 형태학적 관찰을 동반한 결과 24 kDa의 경우 최고 농도인 1.0 mg/mL에서 26.7%를 나타내었으며 4번의 계대 이후에도 형태학적 변화가 나타나지 않아 독성이 없다고 해석할 수 있다. 이후 UVA처리 후 MMP-1의 발현을 탐색한 결과 116 kDa부터 24 kDa까지 최고농도인 1.0 mg/mL에서 40, 46.3, 56.8, 57.9, 62.4%의 control 대비 저해율을 보였다. 외부적 스트레스인 UVA에 의한 AP-1의 활성도를 증가시키는 과정을 억제한 것으로 볼 수 있으며 결과적으로 MMP-1의 발현을 효과적으로 조절한 것이라 사료되어 향후 불가사리 콜라겐 유래 펩타이드의 향장소재 활용 가능성이 높다고 할 수 있겠다.

• Toxicological Research
• /
• 제18권4호
• /
• pp.349-354
• /
• 2002

Inflammatory bowel disease (IBD) is a multifactorial disorder with unknown etiology and pathogenesis. Eupatilin, a kind of flavonoids, has been known to be effective for chronic diarrhea in Korea. In this study, we have investigated the genotoxicity of DA-6034, a new synthetic derivative of Eupatilin, wing in vitro and in viuo system such as Ames reverse mutation test, chromosomal aberration test and micronucleus test. in Ames reverse mutation test, DA-6034 treatment at the dose range up to 5,000 $\mu\textrm{g}$/ plate did not induced mutagenicity in Salmonella typhimurium TA98, TA100, TA102, TA1535, TA1537 with and without metabolic activation. Any significant aberration wasn't observed in chinese hamster lung(CHL) fibroblast cells treated with DA-6034 at the concentration of 5, 2.5, 1.25 mg/ml both in the absence and presence of metabolic activation system. In mouse micronucleus test, no significant increase in the occurrence of micronucleated polychromatic erythrocytes was observed in ICR male mice orally administered with DA-6034 of the doses of 2.0, 1.0, 0.5 g/kg. These results indicate that DA-6034 has no mutagenic potential under the condition in this study.

• Biomolecules & Therapeutics
• /
• 제5권2호
• /
• pp.202-210
• /
• 1997

Protective effect of DA-9601, an extract of Artemisia Herb, against ethanol-induced gastric mucosal injury was evaluated in rats. In the prophylactic study, DA-9601 exhibited total protection (99.4%) against absolute ethanol-induced gastropathy, And the protective effect of DA-9601 lasted up to 2 hours, which was longer than those of other contemporary mucoprotectants. In the treatment study, DA-9601 significantly facilitated the healing of 70% ethanol-induced mucosal damage, which was superior to cetraxate, a commonly used anti-ulcer drug. The mechanisms of mucoprotection of DA-9601 were also assessed. DA-9601 increased the release of prostaglandin E$_2$ from murine neutrophils in a dose-dependent manner in vitro. The cytoprotective effect of DA-9601 against ethanol-induced mucosal damage was significantly diminished by the concommitant injection of N$\omega$-nitro-L-arginine methyl ester (L-NAME, 5 mg/kg, i.v.), a non-specific nitric oxide (NO) synthase inhibitor, while it was not affected by preinjection of indomethacin (5 mg/kg, s.c.), a prostaglandins-depletor. And it was found that DA-9601 significantly enhanced adaptive cytoprotective action of 10% ethanol against absolute ethanol (56.9$\pm$6.5 vs 23.0$\pm$3.3 mm$^2$, p<0.05, mean$\pm$SEM), though its exact underlying mechanism remains to be clarified. The present fin[lings demonstrate that DA-9601 exerts gastroprotecticv actions for the stomach against ethanol through several different underlying mechanisms, in which prostanglandins and NO are involved. In conclusion, the results obtained suggest that DA-9601 can be useful both in prevention and treatment of ethanol-induced gastric damage.

• Biomolecules & Therapeutics
• /
• 제11권1호
• /
• pp.41-50
• /
• 2003

General pharmacological properties of DA-8159, a new pyrazolopyrimidinone derivative were examined in laboratory animals to investigate its safety profile. The oral administration of DA-8159 (1, 5 or 30 mg/kg) in mice and rats had no effect on general behaviors and central nervous system of the animals in test systems, such as hexobarbital-induced sleeping time, motor coordination, normal body temperature, writhing syndromes induced by 0.75% acetic acid solution, chemo-shock produced by pentetrazole solution and rotar rod test. Anesthetized cats treated intravenously with DA-8159 (0.1, 0.3, 1, 3 or 10 mg/kg) showed transient and mild decrease in blood pressure. However, heart rate, respiration rate and tidal volume were not changed by intravenous DA-8159. In the isolated organs including ileum, heart (sinus rate of atria and contractility of papillary muscle), trachea of guinea pigs and phrenic nerve of rats, DA-8159 ($10^{-8}$ ∼$10^{-5}$ mg/L) did not elicit any effect or inhibitory action on the chemically or electrically stimulated contraction. DA-8159 did not influence gastric secretion, pH and total acid output in rats and intestinal propulsion in mice. The administration of DA-8159 in rats had no effect on the platelet aggregation induced by ADP in rabbit plasma, urinary volume and electrolyte ion ($Na^{+}$, $K^{+}$, $Cl^{-}$) excretion in rats. Prothrombin time (PT) of the rats showed a mild but significant increase after administration of DA-8159. Activated partial thromboplastin time (APTT), however, was not affected by DA-8159. These results indicate that DA-8159 does not exert any of serious pharmacological effects.

• Parasites, Hosts and Diseases
• /
• 제32권2호
• /
• pp.111-116
• /
• 1994

우리나라 소에 유행하고 있는 Theileria sergenti의 예방을 위한 연구의 일환으로 긴sergeki merozoite 수용성 항원중에서 면역원성 물질로 보고한 바 있는 34. 29 및 18 kDa와 항원성 물질인 45 kDa에 대하여 Peptdie 구성 특성을 밝히기 위하여. 이들 물질에 대한 아미노산 서열을 결정하였다. 이를 생합성하여 Chou-Fasmanprediction법에 의해 항원 결정기를 확인하였던 바. 45 kDa. 34 kDa. 29 kDa 그리고 18 kDa의 Polypeptide는 6 4 2 그리고 0 개의 항원 결정기를 갖고 있었다. 그런데 45 kDa 물질은 항 T. serpenti혈청에 대하여 면역원성이 인정되않았던 물질이었다.

• Toxicological Research
• /
• 제12권1호
• /
• pp.101-111
• /
• 1996

The local irritation studies of DA-3285, recombinant human erytropoietin(rHu-EPO), were carried out in rabbits after the following treatment; single application into the conjunctival sac of the eye, single subcutaneous injection, 7-day repeated subcutaneous injection and 8-day repeated infusion into the ear vein. Also, the local irritancy of DA-3285 leaked around vein was studied in mice by single perivascular injection. The results obtained were as follows. In the result of ocular irritation test, DA-3285 could be considered as a non-irritating material. In single and 7-day repeated subcutaneous irritation test, the irritancy of DA-3285 was not so much different from that of saline. The vascular irritancy of DA3285 by 8-day repeated infusion was negligible and similar to that of saline. And the irritancy of DA3285 by perivascular injection was comparable to that of saline. These results indicate that DA-3285 has no irritating activity when injected through subcutaneous or intravenous route for clinical practice as 3.5% solution.

• Biomolecules & Therapeutics
• /
• 제4권4호
• /
• pp.354-363
• /
• 1996

This study was conducted to investigate the repeated dose toxicity of DA-9601, an antiulcer agent of Artemisia app. extract, in rats. DA-9601 was administered orally once a day for 4 weeks to 10 males and 10 females per group at doses of 0(vehicle control), 125, 500 or 2000 mg/kg/day. Throughout the study, no treatment-related deaths and clinical signs were observed. In female rats receiving 125 mg/kg of DA-9601, water consumption increased slightly on day 4, 11 and 25. Hematological examination showed a decrease of MCV and an increase of PLT in male rats at the doses of 500 and 2000 mg/kg groups. Blood biochemistry revealed slight decreases of cholesterol, BUN and Na in male rats and decreases of total bilirubin and creatinine and slight increases of globulin and Cl in female rats. The organ weights at the end of 4 weeks showed slight changes in some organs of treated groups. But, all these changes were not considered to be of toxicological importance, because they did not show dose-response relationship and relevance to gross and microscopic findings. Histopathologically, abnormal treatment-related changes were not observed in any organ and target organs were not detected. On the basis of these results, the NOAEL(no-observed-adverse-effect level) of DA-9601 was estimated to be more than 2000 mg/kg/day under the conditions tested.

• 한국해양학회지:바다
• /
• 제20권1호
• /
• pp.1-15
• /
• 2015

한반도 주변을 연구해역으로 하는 지역 해양순환예측시스템을 이용하여 관측기반의 분석 자료인 Operational Sea Surface Temperature and Sea Ice Analysis(OSTIA) 해수면 온도 자료의 동화를 통한 초기장 개선효과가 황해, 동중국해 그리고 동해의 해수면온도 예측결과에 미치는 영향을 조사하였다. 이를 위해서, 본 연구에서는 3차원 최적내삽법을 적용한 실험(Exp. DA)과 적용하지 않은 실험(Exp. NoDA)을 수행하여 각각의 실험결과를 관측자료와 비교 분석하였다. 2011년 9월 OSTIA 해수면 온도 자료와의 비교결과, Exp. NoDA는 24, 48, 72 예측시간에서 약 $1.5^{\circ}C$의 비교적 높은 Root Mean Square Error(RMSE)를 보였으나, Exp. DA에서는 모든 예측시간에서 $0.8^{\circ}C$ 이하의 상대적으로 낮은 RMSE가 나타났다. 특히, 초기 24시간 예측결과에서 RMSE는 $0.57^{\circ}C$를 보여 Exp. NoDA에 비해 예측성능이 크게 향상된 결과를 보였다. 해역별로는 황해와 동해에서 자료동화 적용 시, 60% 이상의 높은 RMSE 감소율이 나타났다. 기상청 8개 지점 연안 계류부이의 표층수온 자료를 이용하여 자료동화 효과를 계절적으로 살펴본 결과, 전반적으로 여름철을 제외한 모든 계절에서 자료동화 적용 후 70% 이상의 높은 RMSE 감소율을 보여 한반도 연안 표층수온의 단기 예측성이 향상됨을 확인하였다. 또한, 해수면 온도 자료의 동화로 인한 해양상층부의 수온구조 변화를 살펴보기 위해 동해를 대표해역으로 하여 Argo 수온 프로파일 자료와 실험결과를 비교하였다. 특히 연직 혼합이 강한 겨울철 해양 상층부(<100 m) 경우 Exp. DA의 RMSE가 Exp. NoDA에 비해 약 $1.5^{\circ}C$ 감소한 결과를 보여 해수면 온도의 자료동화 효과가 해양상층부의 수온 예측성 향상에 기여함을 확인하였다. 하지만, 겨울철 혼합층 아래에서는 Argo 관측 대비 수온 오차가 오히려 증가한 해역도 존재하여 해수면 온도 자료동화의 한계성도 나타났다.

• Biomolecules & Therapeutics
• /
• 제3권1호
• /
• pp.38-46
• /
• 1995

DA-125, a new anthracycline antitumor antibiotic, was administered at dose levels of 0, 0.04, 0.2 and 1.0 mg/kg/day intravenously to pregnant and subsequently delivered Sprague-Dawley rats from day 17 of gestation to day 21 of lactation. Effects of test agent on general toxicity of dams and growth, behaviour and mating performance of F1 offspring were examined. At 1 mg/kg, one out of the twentytwo dams showed difficult delivery, characterized by a stillbirth. Reduction in body weight, loss in food intake, and decrease in spleen weight were also observed in dams. In addition, the lower rates of successful performances in memory test (28.6%) and necrosis of tail end (9.5%) were seen in F1 offspring. At 0.04 and 0.2 mg/kg, no toxic effect on dams and F1 offspring was observed. There were no malformed Fl and F2 fetuses in all groups. The results indicate that the no effect dose levels(NOELs) of DA-125 are 0.2 mg/kg/day for dams and Fl offspring, and over 1 mg/kg/day for F2 fetuses.

• Biomolecules & Therapeutics
• /
• 제2권1호
• /
• pp.94-101
• /
• 1994

DA-125, a new anthracycline antitumor antibiotic, was at dose levels of 0, 0.03, 0.1 and 0.3 mg/kg/day administered intravenously to Sprague-Dawley male rats from premating to mating period and to females from premating to early gestation period. Effects of test agent on general findings and reproductive performance of parent animals and embryonic development were examined. No treatment-related changes in clinical signs, body weight, food consumption and necropsy findings were observed in all groups of both sexes. At 0.3 mg/kg, a decrease in the weight of spleen was found only in male rats. Mating performance and fertility of parent animals were not adversely affected by all doses tested. Fl fetuses showed no changes related to treatment of DA-125, except that at 0.3 mg/kg, an increase in the resorption rate was seen. The results show that the no effect dose levels (NOELS) for general toxicity of parent animals and fetal development are 0.1 mg/kg/day and NOELS for reproductive capability are over 0.3 mg/kg/day.